Clinical Trials · NCT03130426

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

CompletedPhase 3Lixisenatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Population Health Research Institute
Enrollment
161
Start date
Jun 2017
Locations
8 sites, Canada
Primary endpoint
The first occurrence of diabetes relapse
View Lixisenatide compound reference